Transocean has delivered one of the sharpest short-term recoveries in its peer group — up 14% on the week and 25% in a month — yet the short book has barely budged, keeping the tension between price and positioning unusually high.
Short interest is the defining feature of the setup right now. Nearly one in five freely traded shares is sold short, with SI % of free float running at 19.5%. That figure has crept up 4.3% over the past week and about 8.4% over the month, even as the stock climbed from below $6 to close at $7.45. Shorts are not capitulating. They are rebuilding into strength, suggesting the bear case is a conviction view rather than a momentum trade being squeezed out.
The lending market, however, is not signalling stress. Borrow availability is wide — roughly 293% of the current short position is still sitting in the lending pool, well above the 52-week floor of 112%. Cost to borrow has crept higher, up 27% week-on-week to 0.49%, but the absolute level remains low. That combination tells a specific story: there are a lot of shorts, but there is no scramble for stock and no sign of forced cover. Options traders echo the calm — the put/call ratio at 0.62 is running a full standard deviation below its 20-day average of 0.66, meaning call activity is unusually dominant. Buyers are not hedging into this rally; they are leaning into it.
The Street is tentatively turning more constructive, but the mean price target of $6.30 still sits below the current price of $7.45, making consensus a mild headwind rather than a tailwind. The most notable recent move came from Barclays on May 7, when analyst Eddie Kim upgraded to Overweight and lifted his target from $6 to $8 — the clearest institutional endorsement of the move. Morgan Stanley raised its target to $7 in mid-April and TD Cowen lifted to $6 in early May, both maintaining neutral stances. The analyst recommendation differential ranks in the 95th percentile of the market, meaning the spread between buy and sell ratings is historically wide and tilted bullish, even if price targets haven't caught up to reality. EV/EBITDA is running at around 10x on the snapshot data and nearer 8.6x on forward estimates, which is not demanding for an offshore driller in an up-cycle. Net debt remains substantial at roughly $4.3 billion, and interest expense ($599 million annually) continues to consume a meaningful slice of operating cash flow.
Two institutional flows are worth noting. Slate Path Capital entered the register in Q1 with a clean 30 million-share new position. D.E. Shaw and Two Sigma — both quantitative shops — added around 22-23 million shares each. These are not passive index additions; they suggest systematic models found the setup attractive around the $6 level. Dimensional also added 5.3 million shares. On the insider side, the CEO sold 71,556 shares on May 4 at $6.82 as part of what appears to be award-related activity, with a corresponding stock award on May 1. The 90-day insider net is modestly positive at $14.5 million in value terms, largely reflecting award grants rather than open-market buying — not a strong signal in either direction.
Earnings history is directly relevant. Transocean reported Q1 2026 results on May 5 and the stock fell 9.4% the next day, extending to roughly -4.9% over the following five trading sessions. That kind of post-earnings drop — with the stock down nearly 9-10% in a single session — has been the pattern. The company reports Q2 on July 27. The current 14% weekly surge appears to have absorbed some of that post-earnings hangover and then some. How the shorts respond as that next print approaches — and whether the Barclays upgrade draws further institutional accumulation — are the two threads worth watching into summer.
See the live data behind this article on ORTEX.
Open RIG on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
